Last reviewed · How we verify
Proton pump inhibitor (PPI)
Proton pump inhibitors block the hydrogen/potassium ATPase enzyme in gastric parietal cells, reducing gastric acid secretion.
Proton pump inhibitors block the hydrogen/potassium ATPase enzyme in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Proton pump inhibitor (PPI) |
|---|---|
| Also known as | omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole |
| Sponsor | IBSA Institut Biochimique SA |
| Drug class | Proton pump inhibitor |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
PPIs irreversibly inhibit the final step of gastric acid production by targeting the proton pump (H+/K+-ATPase) on the secretory surface of parietal cells. This leads to sustained suppression of both basal and stimulated acid secretion, raising intragastric pH and reducing acid-related damage to the gastrointestinal mucosa.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Hypomagnesemia (chronic use)
- Vitamin B12 deficiency (chronic use)
- Clostridium difficile infection (increased risk)
Key clinical trials
- Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD (PHASE2)
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial. (NA)
- OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (PHASE4)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction (PHASE4)
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (PHASE2)
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Proton pump inhibitor (PPI) CI brief — competitive landscape report
- Proton pump inhibitor (PPI) updates RSS · CI watch RSS
- IBSA Institut Biochimique SA portfolio CI